CTIS2023-508992-35-00进行中（未招募）1 期
A Phase 2b Multicenter, Randomized, Double-blind, Placebo-controlled Dose-Ranging Study to Evaluate the Efficacy and Safety of JNJ-81241459 for the Treatment of Participants with Moderate to Severe Plaque Psoriasis
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 200
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- •Be =18 (or the legal age of consent if it is higher in the jurisdiction in which the study is taking place) years of age at screening, inclusive., Diagnosis of plaque psoriasis, Total BSA =10% at screening and baseline., Total PASI =12 at screening and baseline., Total IGA =3 at screening and baseline.
排除标准
- •Nonplaque form of psoriasis (eg, erythrodermic, guttate, or pustular)., Current drug-induced psoriasis (eg, a new onset of psoriasis or an exacerbation of psoriasis from beta blockers, calcium channel blockers, or lithium)., A current diagnosis or signs or symptoms of severe, progressive, or uncontrolled renal, liver, cardiac, vascular, pulmonary, gastrointestinal, endocrine, neurologic, hematologic, rheumatologic, psychiatric, or metabolic disturbances., A current diagnosis or history of IBD., Known allergies, hypersensitivity, or intolerance to JNJ-81241459 or its excipients (refer to the JNJ-81241459 IB).
研究者
相似试验
进行中（未招募）
1 期
A clinical trial testing different doses of investigational drug ALX-0061 combined with Methotrexate to treat patients with Moderate to Severe Rheumatoid ArthritisRheumatoid Arthritis (RA)MedDRA version: 18.1Level: SOCClassification code 10021428Term: Immune system disordersSystem Organ Class: 10021428 - Immune system disordersEUCTR2014-003033-26-CZAblynx NV330
进行中（未招募）
1 期
A clinical trial testing different doses of investigational drug ALX-0061 combined with Methotrexate to treat patients with Moderate to Severe Rheumatoid ArthritisRheumatoid Arthritis (RA)MedDRA version: 18.1Level: SOCClassification code 10021428Term: Immune system disordersSystem Organ Class: 10021428 - Immune system disordersEUCTR2014-003033-26-DEAblynx NV330
进行中（未招募）
1 期
A clinical trial testing different doses of investigational drug ALX-0061 combined with Methotrexate to treat patients with Moderate to Severe Rheumatoid ArthritisRheumatoid Arthritis (RA)MedDRA version: 17.1Level: SOCClassification code 10021428Term: Immune system disordersSystem Organ Class: 10021428 - Immune system disordersEUCTR2014-003033-26-ESAblynx NV330
进行中（未招募）
1 期
A clinical trial testing different doses of investigational drug ALX-0061 combined with Methotrexate to treat patients with Moderate to Severe Rheumatoid ArthritisRheumatoid Arthritis (RA)MedDRA version: 18.1Level: SOCClassification code 10021428Term: Immune system disordersSystem Organ Class: 10021428 - Immune system disordersEUCTR2014-003033-26-BGAblynx NV330
进行中（未招募）
1 期
A clinical trial testing different doses of investigational drug ALX-0061 combined with Methotrexate to treat patients with Moderate to Severe Rheumatoid ArthritisRheumatoid Arthritis (RA)MedDRA version: 18.0Level: SOCClassification code 10021428Term: Immune system disordersSystem Organ Class: 10021428 - Immune system disordersEUCTR2014-003033-26-BEAblynx NV330